RxDoctor Payments Data

Elisabeth Hudson

Nurse Practitioner · Seguin, TXNPI 1457920142

Payments from drug & device makers

$2,176in general payments, 2019–2025

Across 111 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$663
  • Sanofi$422
  • Actelion Pharmaceuticals US, Inc.$411
  • AstraZeneca$276
  • Tactile Systems Technology Inc$112
  • Sanofi-aventis U.S. LLC$89
  • plus $203 from 7 others

What the payments were for

  • Food & beverage$2,00792%
  • Education$1698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,176 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$69,989
Medicare patients
277
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter376$257,396
Dupixent PenDupilumab53$195,279
MounjaroTirzepatide71$72,126
Dupixent SyringeDupilumab14$61,004
Breztri AerosphereBudesonide/Glycopyr/Formoterol78$50,638
EliquisApixaban31$23,116
Breo ElliptaFluticasone/Vilanterol49$22,040
Advair HfaFluticasone Propion/Salmeterol38$15,734
Spiriva RespimatTiotropium Bromide17$12,776
XareltoRivaroxaban15$12,377
OzempicSemaglutide12$10,923
JardianceEmpagliflozin17$10,458
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$9,726
Incruse ElliptaUmeclidinium Bromide24$8,354
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$7,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$663$292,767461 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$276$63,395117 claims
Boehringer IngelheimSpiriva Respimat, Jardiance, Stiolto Respimat, Synjardy Xr$12$39,59565 claims
Johnson & JohnsonXarelto$34$12,37715 claims
Novo NordiskOzempic$13$10,92312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →